Reuters logo
BRIEF-Immunogen sees FY 2017 revenue $70 mln to $75 mln
2017年2月17日 / 中午11点54分 / 7 个月前

BRIEF-Immunogen sees FY 2017 revenue $70 mln to $75 mln

Feb 17 (Reuters) - Immunogen Inc:

* Immunogen reports recent progress and operating results for six-month period and quarter ended December 31, 2016

* Sees FY 2017 revenue $70 million to $75 million

* Immunogen Inc - first patient enrolled in phase 3 forward I trial of mirvetuximab soravtansine

* Immunogen Inc - sees 2017 revenues between $70 million and $75 million

* Immunogen Inc - sees 2017 operating expenses between $175 million and $180 million

* Immunogen Inc -sees cash and marketable securities at December 31, 2017 between $35 million and $40 million

* Immunogen - expects current cash plus expected cash revenues from partners and collaborators will enable company to fund operations into Q2 of 2018 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below